Wall Street on shrooms, read this https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022

1. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 2/15
PSYCHEDLIC STOCKS
di h ll
 Edit Article (https://cannabis.net/mycannabis/c-blog-entry/update/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022)
 Article List (https://cannabis.net/mycannabis/c-blog)

2. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 3/15
Trading Shrooms on Wall Street -
Psychedelics Stocks and ETFs for 2022
Did you know that companies dealing is psychedlics are publically traded on Wall Street?
Posted by:
HighChi on Thursday Jan 27, 2022
Psychedelics like magic mushrooms, LSD, and MDMA have completed the full race from being outrageously vilified by all
to being accepted by the majority.
In the last year, companies around the world bet on the legalization of the psychedelic industry by establishing major
production spots across the US and Canada. Sadly, the US and Canadian federal governments did not think it was time
yet. Still, they acquiesced enough to permit a limited amount of research to establish if the drugs truly have medical
potential.

3. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 4/15
We're in a period that people have termed "the psychedelic renaissance." Now, everyone is waiting to see if the various
investment hot spots will be worth it by the end of this year. Although the psychedelic industry is relatively new, It can
potentially open doors for investors and entrepreneurs all over the world.
Unveiling Psychedelics
Once scientific evidence showing the therapeutic potential of psychedelics was revealed, these substances became
impossible to ignore. It also posed the need for new industry; the psychedelic industry. The first set of psychedelic
companies announced themselves in 2020 and began scaling up their operations in 2021. Like with the cannabis
industry, the pandemic opened the eyes of many to the potential of psychedelics and caused the budding industry to
enter the mainstream.
Getting to experience creating this new industry from nothing has been incredible these past months for investors,
entrepreneurs, and observers. Dozens of companies are currently processing psychedelic substances into effective
medications. Reports say that these activities are being supported by major U.S. exchanges and legacy investment
banks.
Achievements for 2021
Overall, the psychedelic sector overcame a series of challenges to attain the foundation it now has in the medical
industry. It successfully shifted the paradigm and disrupted mental health treatment to draw attention to the drug's
wonders.
Several Canadian and U.S. psychedelic companies have successfully listed on major exchanges like the NYSE and the
NASDAQ. The industry also penetrated Wall Street, becoming known to thousands of retail investors scattered across
the world. In the 2021 Q4 period, the U.S. already had at least 50 listed psychedelic companies. Of which nine are listed
on the NYSE and NASDAQ.
These companies include Enveric Biosciences, GH Research, Atail Life Sciences, MindMed
(https://cannabis.net/blog/news/first-ever-publicly-traded-psychedelics-company-soars-over-22-on-first-day-of-trading),
Seelos Therapeutics, Compass Pathways, Cybin Corp, Pasithea Therapeutics Corp, and Field Trip Health, Inc.

4. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 5/15
Launching ETFs for psychedelics
About a year ago, the first psychedelics-focused exchange-traded funds were debited on Toronto's NEO exchange. The
ETF, Horizons Psychedelic Stock Index (NEO: PSYK), was launched to focus on the relatively new industry. Less than six
months after this launch, Defiance ETF launched the Defiance Next Gen Altered Experience in the U.S.
Due to the low-key state of the industry then, both ETFs remained passive and focused on tracking a periodically
restructured index.
The only active ETF in the U.S. psychedelic sector is the AdvisorShares Psychedelics ETF, launched in September by
AdvisorShares.
Capital Availability Made Possible By The Private Sector

5. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 6/15
As expected, many companies are getting involved in the industry to make a tremendous amount of profit. In 2021,
dozens of psychedelic start-ups were listed as private entities on the exchanges. This caused an increased in-flow of
capital.
CB Insights reported in November that the estimated equity funding in the sector as of October 31st was about $594
million. This figure was reached when over 40 different deals were struck. In 2020, this figure was less than $400 million.
This year, experts predict that at least 55 other arrangements will be reached, generating over $720 million.
The report showed that about 50% of this private funding was committed to psychedelic research and development.
This niche promises to be the most profitable in the medium term. Records also show that the psychedelic industry
comprises hundreds of new startups, most privately funded—private companies number at least nine times as many as
public-listed companies.
Investment banks have their toes dipped in but remain cautious. Another indication of the psychedelic industry's launch
into mainstream finance is the presence of several investment banks and financial services firms snooping around the
sector. Cantor Fitzgerald, Credit Sissies, Citigroup, Aegis Capital, Canaccord Genuity, RBC Capital Markets, Roth Capital,
Cowen & Co, and Maxim Group, among others, now provide in-depth analysis on the leading psychedelic companies.
The start-ups with the most favorable ratings are often categorized in the Buy or Outperform sections.
The Current State of the Psychedelic Industry
Researchers made substantial progress geared towards having a better understanding of psychoactive substances and
their relations with the human body and mind. UT Austin, the University of Wisconsin, the UC Berkeley Center, New York
University, and the Icahn School of Medicine have all been at the forefront of this research.
This academic research has fostered partnerships between capitalist organizations and educational institutions. Like the
Mycedine innovation being handled by John Hopkins University, it is being funded by the company, the same way Atai is
funding Harvard's Massachusetts research.

6. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 7/15
The media plays a vital role in publicizing the medical benefits of these new drugs. Major news outlets like the New York
Times and the Washington Post have featured and published psychedelic psychedelics as cover stories. A Hulu
miniseries, Nine Perfect Strangers, had psychedelics as its central theme.
The federal government's reluctance to decriminalize psychedelics is not shared by some state governments.
Psychedelic substances have been decriminalized in Detroit, Seattle, and cities in California and Massachusetts. States
like Texas, Florida, Colorado, Vermont, Connecticut, Maine, Missouri, and New York may be passing psychedelics
legislation this year, following the introduction and passing of bills to allow the use and sales of psychoactive drugs.
Bottom Line
The encouragement of academic researchers, constant media presence and the introduction of regulations in some
states mirror the financial tailwinds that are blowing through the industry. So many events, supported by groups and
individuals interested in the budding ecosystem, coincided on large scales during 2021 that nothing less than this is
expected this year. Hopefully, we will see an international psychedelic culture that values the drug for its therapeutic
potential and not just for the economic profits it could bring in.
INVESTING IN CSA STOCKS, READ MORE...
(https://cannabis.net/blog/news/first-ever-publicly-traded-psychedelics-
company-soars-over-22-on-first-day-of-trading)

7. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 8/15
MINDMED SOARS IN FIRST DAYS OF PUBLIC TRADING, READ THIS. (https://cannabis.net/blog/news/first-ever-publicly-
traded-psychedelics-company-soars-over-22-on-first-day-of-trading)
OR...
(https://cannabis.net/blog/interview/cannabis-investors-should-be-
getting-2230-roi-on-their-marijuana-investments)
MARIJUANA SHOULD HAVE AN ROI OF 25% TO 30% SAYS GURU (https://cannabis.net/blog/interview/cannabis-
investors-should-be-getting-2230-roi-on-their-marijuana-investments)
What did you think?
Keep reading... click here
0 0 0 0 0 0

8. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 9/15
(https://cannabis.net/blog)
Leave a Comment:
Submit
What are your thoughts?
CATEGORIES

9. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 10/15
RECIPES (HTTPS://CANNABIS.NET/BLOG/RECIPES) INTERVIEW (HTTPS://CANNABIS.NET/BLOG/INTERVIEW)
TECHNOLOGY (HTTPS://CANNABIS.NET/BLOG/TECHNOLOGY) OPINION (HTTPS://CANNABIS.NET/BLOG/OPINION)
VIDEOS (HTTPS://CANNABIS.NET/BLOG/VIDEOS) MEDICAL (HTTPS://CANNABIS.NET/BLOG/MEDICAL)
PERSONAL STORY (HTTPS://CANNABIS.NET/BLOG/PERSONAL-STORY) SEXY (HTTPS://CANNABIS.NET/BLOG/SEXY)
SPORTS (HTTPS://CANNABIS.NET/BLOG/SPORTS) VOTE (HTTPS://CANNABIS.NET/BLOG/VOTE)
HISTORY (HTTPS://CANNABIS.NET/BLOG/HISTORY) HOW TO (HTTPS://CANNABIS.NET/BLOG/HOW-TO)
VAPING (HTTPS://CANNABIS.NET/BLOG/VAPING) DABS (HTTPS://CANNABIS.NET/BLOG/DABS)
FUNNY (HTTPS://CANNABIS.NET/BLOG/FUNNY) NEWS (HTTPS://CANNABIS.NET/BLOG/NEWS)
STRAINS (HTTPS://CANNABIS.NET/BLOG/STRAINS) LOCATIONS (HTTPS://CANNABIS.NET/BLOG/LOCATIONS)
B2B (HTTPS://CANNABIS.NET/BLOG/B2B) SMOKE (HTTPS://CANNABIS.NET/BLOG/SMOKE)
EVENTS (HTTPS://CANNABIS.NET/BLOG/EVENTS)
CATEGORIES
FEATURED

10. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 11/15
(https://cannabis.net/blog/opinion/is-there-a-best-way-to-consume-cannabis)
OPINION
Is There a Best Way To Consume Cannabis?
You have to find YOUR best method of consumption. It comes down to objectives, desired side-effects catered to your own personal life style. Understand ‘what
you want’ from the cannabis plant will dictate the best approach to achieve your goals.

11. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 12/15
HOW TO
Everything You Need To Know About Flushing Your Cannabis Plants
The purpose of flushing is to get rid of chemicals that may have accumulated in plant tissue so that the plants can absorb nutrients, and excrete the excess
without storing other minerals that it no longer needs.

12. 1/27/22, 7:17 PM Trading Shrooms on Wall Street - Psychedelics Stocks and ETFs for 2022
https://cannabis.net/blog/news/trading-shrooms-on-wall-street-psychedelics-stocks-and-etfs-for-2022 13/15
(https://cannabis.net/blog/how-to/everything-you-need-to-know-about-flushing-your-cannabis-plants)
OPINION
The Billion Dollar Cannabis Industry Debate - Does Branding Really Matter in the Future for Cannabis Products?